Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 18/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171187 | 0.81 | GRM2 (0.54) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL4129495 | 0.80 | LMNA (0.60) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL169741 | 0.79 | GRM2 (0.64) | GRM2 | |
| SCHEMBL1827879 | 0.78 | GRM2 (0.59) | GRM2 | |
| SCHEMBL4140192 | 0.75 | SCN9A (0.33) | GRM2KDM4EALDH1A1 | |
| SCHEMBL4143914 | 0.74 | GRM2 (0.31) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL259368 | 0.74 | MAPT (0.59) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL16019365 | 0.73 | PGR (0.37) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL171733 | 0.72 | GRM2 (0.46) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL4062856 | 0.72 | ALDH1A1 (0.48) | GRM2KDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | GRM2 3863/4885KDM4E 3676/4885ALDH1A1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.